TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Hematology & Oncology
Division of Radiation Therapy
Division of Urology
Division of Nuclear Medicine
Division of Radiology
更新時間：2023-09-19
成佳憲Chen, Chia-Hsien
- Principal Investigator
- Clinical Trial Experience (year) 12 years 9 個月
Publication
95Publications
21
Tsai YC, Ho PY, Tzen KY, Tuan TF, Liu WL, Cheng AL, Pu YS, Cheng JC*. Synergistic blockade of EGFR and HER2 by new generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells. Molecular Cancer Therapeutics 14:810-820, 2015 (SCI)
22
Tsai CL, Hsu FM, Tzen KY, Liu WL, Cheng AL, Cheng JC*. Sonic hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 30:1317-1324, 2015 (SCI)
23
Lu SL, Hsu FM, Tsai CL, Wu JK, Lee JM, Huang PM, Hsu CH, Koong AC, Chang DT, Cheng JC*. Serum transforming growth factor-β1 change after neoadjuvant chemoradiotherapy is associated with postoperative pulmonary complications in esophageal cancer patients undergoing combined modality therapy. International Journal of Radiation Oncology, Biology, Physics 93:1023-1031, 2015 (SCI)
24
Wang YJ, Huang CY, Hou WH, Wang CC, Lan KH, Chen CH, Yu HJ, Lai MK, Cheng AL, Liu SP, Pu YS, Cheng JC*. The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer. World Journal of Surgical Oncology 13:312, 2015 (SCI)
25
Liu WL, Gao M, Tzen KY, Tsai CL, Hsu FM, Cheng AL, Cheng JC*. Targeting phosphatidylinositide3-kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget 5:3662-3672, 2014 (SCI)
26
Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, Chang DT, Koong AC*. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy. Annals of
Surgical Oncology 21:2361-2368, 2014 (SCI)
Surgical Oncology 21:2361-2368, 2014 (SCI)
27
Lin ZZ, Chou CH, Cheng AL, Liu WL*, Cheng JC*. Radiosensitization by combining an Aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption. International Journal of Cancer 135:492-501, 2014 (SCI)
28
Wang CC, Liang JT, Tsai CL, Chen YH, Lin YL, Shun CT, Cheng JC*. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. World Journal of Surgical Oncology 12:329, 2014 (SCI)
29
Cheng JC, Bazan JG, Wu JK, Koong AC, Chang DT. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Practical Radiation Oncology 4:198-206, 2014 (SCI)
30
Tsai YC, Yeh CH, Tzen KY, Ho PY, Tuan TF, Pu YS, Cheng AL, Cheng JC*. Targeting EGFR/HER2 signaling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitization in murine bladder carcinoma. European Journal of Cancer 49:1458-1466, 2013 (SCI)
